Phase I Study of IMA401 TCER® in Patients with Solid Tumors: Monotherapy and Combination with Checkpoint Inhibitor

The primary objective of the study is to evaluate the safety and tolerability of **IMA401 TCER®**, a bispecific T-cell receptor, in patients with **solid tumors**. This is a Phase I trial assessing the treatment both as a monotherapy and in combination with a checkpoint inhibitor. The clinical relevance of this study lies in its potential to offer a novel therapeutic approach for patients with solid tumors, which are often challenging to treat with conventional therapies.

The clinical trial involves participants diagnosed with **solid tumors**. The study population includes both male and female subjects, encompassing an **age range** of 18 to 64 years. The trial population selection criteria include individuals from a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, and habits, as well as key inclusion or exclusion criteria, are not specified in the available data.

The clinical trial is designed to evaluate the safety and efficacy of **IMA401 TCER®** in patients with **solid tumors**. This is a Phase I trial, which will be conducted as a randomized, double-blind, controlled study. The trial is expected to commence recruitment on May 19, 2022, and is projected to conclude by December 31, 2029. Participants will be randomly assigned to receive either the investigational product alone or in combination with a checkpoint inhibitor. The trial will follow a structured sequence of study visits, beginning with an inclusion visit, where participants will undergo screening to determine eligibility based on predefined criteria. Subsequent follow-up visits will be scheduled to monitor the participants' response to the treatment and to assess any adverse events. The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted to evaluate the overall outcomes of the treatment. The expected duration of participant involvement will vary, but it is anticipated to last until the end of the study period unless early termination is warranted. Conditions that may lead to early termination include the occurrence of significant adverse events, withdrawal of consent, or any other protocol-defined criteria. The trial aims to gather comprehensive data on the investigational product's safety profile and its potential therapeutic benefits in treating solid tumors.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments involved in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, focusing on initial safety and efficacy assessments. The estimated recruitment start date is May 19, 2022, with an anticipated end date of December 31, 2029. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve the collection of preliminary data on the intervention's effect on the disease. The trial will likely employ standardized methods for measuring and analyzing efficacy, which may include validated scales, laboratory tests, or patient-reported outcomes, depending on the nature of the intervention and the disease being studied. The schedule for these assessments is not specified, but they are typically conducted at various timepoints throughout the trial to monitor changes and trends in efficacy. The trial's design will ensure that data collection and analysis are conducted in a manner that adheres to regulatory standards and scientific rigor.